Chimeric antigen receptor T-cell therapy

Ndiya Ogba; Nicole M. Arwood; Nancy L. Bartlett; Mara Bloom; Patrick Brown; Christine Brown; Elizabeth Lihua Budde; Robert Carlson; Stephanie Farnia; Terry J. Fry; Morgan Garber; Rebecca A. Gardner; Lauren Gurschick; Patricia Kropf; Jeff J. Reitan; Craig Sauter; Bijal Shah; Elizabeth J. Shpall; Steven T. Rosen

doi:10.6004/jnccn.2018.0073

Chimeric antigen receptor T-cell therapy

Ndiya Ogba, Nicole M. Arwood, Nancy L. Bartlett, Mara Bloom, Patrick Brown, Christine Brown, Elizabeth Lihua Budde, Robert Carlson, Stephanie Farnia, Terry J. Fry, Morgan Garber, Rebecca A. Gardner, Lauren Gurschick, Patricia Kropf, Jeff J. Reitan, Craig Sauter, Bijal Shah, Elizabeth J. Shpall, Steven T. Rosen

Stem Cell Transplantation

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.

Original language	English (US)
Pages (from-to)	1093-1106
Number of pages	14
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	16
Issue number	9
DOIs	https://doi.org/10.6004/jnccn.2018.0073
State	Published - Sep 1 2018

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2018.0073

Cite this

Ogba, N., Arwood, N. M., Bartlett, N. L., Bloom, M., Brown, P., Brown, C., Budde, E. L., Carlson, R., Farnia, S., Fry, T. J., Garber, M., Gardner, R. A., Gurschick, L., Kropf, P., Reitan, J. J., Sauter, C., Shah, B., Shpall, E. J., & Rosen, S. T. (2018). Chimeric antigen receptor T-cell therapy. JNCCN Journal of the National Comprehensive Cancer Network, 16(9), 1093-1106. https://doi.org/10.6004/jnccn.2018.0073

Ogba, N, Arwood, NM, Bartlett, NL, Bloom, M, Brown, P, Brown, C, Budde, EL, Carlson, R, Farnia, S, Fry, TJ, Garber, M, Gardner, RA, Gurschick, L, Kropf, P, Reitan, JJ, Sauter, C, Shah, B, Shpall, EJ & Rosen, ST 2018, 'Chimeric antigen receptor T-cell therapy', JNCCN Journal of the National Comprehensive Cancer Network, vol. 16, no. 9, pp. 1093-1106. https://doi.org/10.6004/jnccn.2018.0073

@article{3e4067dd2158426fb241113d8028021b,

title = "Chimeric antigen receptor T-cell therapy",

abstract = "Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin{\textquoteright}s lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.",

author = "Ndiya Ogba and Arwood, {Nicole M.} and Bartlett, {Nancy L.} and Mara Bloom and Patrick Brown and Christine Brown and Budde, {Elizabeth Lihua} and Robert Carlson and Stephanie Farnia and Fry, {Terry J.} and Morgan Garber and Gardner, {Rebecca A.} and Lauren Gurschick and Patricia Kropf and Reitan, {Jeff J.} and Craig Sauter and Bijal Shah and Shpall, {Elizabeth J.} and Rosen, {Steven T.}",

note = "Publisher Copyright: {\textcopyright} JNCCN—Journal of the National Comprehensive Cancer Network.",

year = "2018",

month = sep,

day = "1",

doi = "10.6004/jnccn.2018.0073",

language = "English (US)",

volume = "16",

pages = "1093--1106",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "9",

}

TY - JOUR

T1 - Chimeric antigen receptor T-cell therapy

AU - Ogba, Ndiya

AU - Arwood, Nicole M.

AU - Bartlett, Nancy L.

AU - Bloom, Mara

AU - Brown, Patrick

AU - Brown, Christine

AU - Budde, Elizabeth Lihua

AU - Carlson, Robert

AU - Farnia, Stephanie

AU - Fry, Terry J.

AU - Garber, Morgan

AU - Gardner, Rebecca A.

AU - Gurschick, Lauren

AU - Kropf, Patricia

AU - Reitan, Jeff J.

AU - Sauter, Craig

AU - Shah, Bijal

AU - Shpall, Elizabeth J.

AU - Rosen, Steven T.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.

AB - Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.

UR - http://www.scopus.com/inward/record.url?scp=85053000143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053000143&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2018.0073

DO - 10.6004/jnccn.2018.0073

M3 - Article

C2 - 30181421

AN - SCOPUS:85053000143

SN - 1540-1405

VL - 16

SP - 1093

EP - 1106

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 9

ER -

Chimeric antigen receptor T-cell therapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this